Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Chief Financial Officer | December 31, 2022 | May 08, 2023 |
| Lite Strategy, Inc.LITS · Entity 7396 | Director · CEO, CFO and Secretary | February 12, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date December 31, 2022 · Filed May 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,065 |
Reported balance
After 2022-12-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-31 · Disposition to issuer · Disposed 30,000 · Balance 24,065 F1: The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/18/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/18/2022.
Lite Strategy, Inc.
Report date February 12, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-11-20 | Direct | 635,000 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 455,000 · Balance 635,000 F1: The option grant was approved by the LITS board of directors on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan under which the options were granted. LITS shareholders approved the plan on February 12, 2026. F3: Received as employment compensation. F2: Such option shall be 5.6% vested and exercisable as of the February 12, 2026. The remaining 94.4% shall vest and become exercisable in 34 monthly installments, beginning on February 14, 2026, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the LITS board of directors on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan under which the options were granted. LITS shareholders approved the plan on February 12, 2026.
F2: Such option shall be 5.6% vested and exercisable as of the February 12, 2026. The remaining 94.4% shall vest and become exercisable in 34 monthly installments, beginning on February 14, 2026, subject to continued service through the applicable vesting date.
F3: Received as employment compensation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 12, 2026 17:44 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 455,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-26-049089 · ownership.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,000 Underlying: Common Stock · 455,000 shares Expires 2035-11-20 F1 · date: The option grant was approved by the LITS board of directors on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan under which the options were granted. LITS shareholders approved the plan on February 12, 2026. F3 · price: Received as employment compensation. F2 · derivative.exercise_date: Such option shall be 5.6% vested and exercisable as of the February 12, 2026. The remaining 94.4% shall vest and become exercisable in 34 monthly installments, beginning on February 14, 2026, subject to continued service through the applicable vesting date. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 17:07 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 635,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-286426 · ownership.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,000 Underlying: Common Stock · 635,000 shares Expires 2035-11-14 F2 · price: Received as employment compensation. F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date. Read SEC document |
| November 14, 2025 Filed Nov 20, 2025 17:29 UTC Amendment | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 180,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-290061 · ownership.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-11-14 F3 · price: Received as employment compensation. F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date. F2 · derivative.exercise_date: On November 18, 2025, the reporting person filed a Form 4 which inadvertently reported the number options granted to such reporting person. In fact, as reported in this amendment, the reporting person was granted 180,000 options. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:36 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000929638-25-002635 · form4.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Secretary, Acting CEO & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-07-15 F1 · security: Customary annual grant to executives of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025. Read SEC document |
| December 31, 2022 Filed May 8, 2023 16:05 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Disposition to issuerCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-015782 · ownership.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,065 F1 · security: The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/18/2022. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:06 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001618835-22-000030 · wf-form4_164565040087112.xml · derivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-02-18 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:06 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-22-000030 · wf-form4_164565040087112.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,982 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:05 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Disposition to issuerCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-22-000005 · wf-form4_164133028601106.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,982 F1 · security: The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/3/2021. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 16:20 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 40,594 | $0.37 | $15,019.78 |
DisclosureSEC source: 0001618835-21-000272 · wf-form4_164003518854810.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,982 Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 19:30 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 24,500 | $1.03 | $25,235.00 |
DisclosureSEC source: 0001618835-21-000148 · wf-form4_162336780990730.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,388 Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:25 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 42,280 | $0.86 | $36,360.80 |
DisclosureSEC source: 0001618835-21-000134 · wf-form4_162162874189569.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,888 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 20:00 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000011 · wf-form4_161240037364841.xml · derivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 20:00 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-21-000011 · wf-form4_161240037364841.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,168 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 17:22 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 7,760 | $2.17 | $16,839.20 |
DisclosureSEC source: 0001618835-20-000248 · wf-form4_160573815596283.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,168 F1 · security: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.16 to $2.18, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 16:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 8,500 | $3.14 | $26,690.00 |
DisclosureSEC source: 0001618835-20-000194 · wf-form4_159225215860208.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,408 F1 · balance_after: The total amount of securities beneficially owned includes 4,303 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:43 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 42,810 | $3.31 | $141,701.10 |
DisclosureSEC source: 0001618835-20-000189 · wf-form4_159165258593749.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,605 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:15 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 42,262 | $4.99 | $210,887.38 |
DisclosureSEC source: 0001618835-20-000155 · wf-form4_159052772480668.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,415 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 12:31 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 8,420 | $5.24 | $44,120.80 |
DisclosureSEC source: 0001618835-20-000113 · wf-form4_158895547746701.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,677 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001618835-20-000020 · wf-form4_158111115041172.xml · derivative · entry 3 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F5 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000020 · wf-form4_158111115041172.xml · nonDerivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,097 F4 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 3,846 | $5.21 | $20,037.66 |
DisclosureSEC source: 0001618835-20-000020 · wf-form4_158111115041172.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,097 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Evofem Biosciences, Inc. 2019 Employee Stock Purchase Plan (2019 ESPP), for the ESPP purchase period of June 17, 2019 through December 13,2019. This transaction is also exempt under Rule 16b-3(c). F2 · date: The reporting person is voluntarily reporting this transaction as of February 5, 2020, but the actual transaction took place on December 13, 2019, the last trading day of the purchase period under the 2019 ESPP. F3 · shares: In accordance with the 2019 ESPP, these shares were purchased based on 85% of the closing stock price on December 13, 2019, the last trading day of the purchase period. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 16:22 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 1,648 | $6.00 | $9,888.00 |
DisclosureSEC source: 0001618835-20-000011 · wf-form4_157912333658848.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,251 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 15:07 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 3,352 | $6.05 | $20,279.60 |
DisclosureSEC source: 0001618835-20-000003 · wf-form4_157834125799228.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,899 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 17:33 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 10,000 | $7.16 | $71,600.00 |
DisclosureSEC source: 0001618835-19-000213 · wf-form4_157549880669694.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,251 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 17:14 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 10,102 | $6.22 | $62,834.44 |
DisclosureSEC source: 0001618835-19-000201 · wf-form4_157480644392728.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,251 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 25, 2019. No shares were sold in connection with this transaction. Read SEC document |
| November 21, 2019 Filed Nov 21, 2019 20:18 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 4,900 | $6.00 | $29,400.00 |
DisclosureSEC source: 0001618835-19-000183 · wf-form4_157438547271990.xml · nonDerivative · entry 3 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,353 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2019. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 20:18 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 100 | $6.00 | $600.00 |
DisclosureSEC source: 0001618835-19-000183 · wf-form4_157438547271990.xml · nonDerivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,253 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2019. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 20:18 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 10,102 | $5.74 | $57,985.48 |
DisclosureSEC source: 0001618835-19-000183 · wf-form4_157438547271990.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,353 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 20, 2019. No shares were sold in connection with this transaction. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 18:36 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 1,558 | $5.13 | $7,992.54 |
DisclosureSEC source: 0001618835-19-000153 · wf-form4_156685895058061.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,455 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on August 22, 2019. No shares were sold in connection with this transaction. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:39 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 10,185 | $6.36 | $64,776.60 |
DisclosureSEC source: 0001618835-19-000125 · wf-form4_156037193526871.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,013 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 10, 2019. No shares were sold in connection with this transaction. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:43 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 1,292 | $3.55 | $4,586.60 |
DisclosureSEC source: 0001618835-19-000050 · wf-form4_155433137081269.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,198 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on April 1, 2019. No shares were sold in connection with this transaction. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:11 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000021 · wf-form4_155130188278594.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,490 F1 · kind: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2019. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 18:11 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000118 · wf-form4_154353305044025.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,500 Underlying: Common Stock · 0 shares Expires 2028-11-28 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. Read SEC document |
| November 28, 2018 Filed Dec 3, 2018 12:50 UTC Amendment | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 103,500 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000128 · wf-form4a_154385943828394.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,500 Underlying: Common Stock · 103,500 shares Expires 2028-11-28 F1 · shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. F1 · derivative.underlying_shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:25 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000079 · wf-form4_153324153509644.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 114,000 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:59 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 119,510 | $2.46 | $293,994.60 |
DisclosureSEC source: 0001618835-18-000049 · wf-form4_153065157996681.xml · nonDerivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,490 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:59 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000049 · wf-form4_153065157996681.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019636 · doc4.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. File acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Mr. File's service as Chief Financial Officer. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:03 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock Option (right to buy) · Derivative | 10,266 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004299 · doc4.xml · derivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,266 Underlying: Common Stock · 10,266 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F4 · derivative.exercise_date: Mr. File acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2017 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2020, subject to Mr. File's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:03 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock Option (right to buy) · Derivative | 12,833 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004299 · doc4.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,833 Underlying: Common Stock · 12,833 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Mr. File acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Mr. File's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.